some light reading for your Saturday morninghttps://www.sciencedirect.com/science/article/pii/S0969996120302850
A brilliant and extensive overview of the monoclonal antibodies out there targeting amyloid beta, and (briefly) why Promis' PMN 310 antibody is theorized to be best in class with respect to ARIA-E associated dosing limitations.
This was published in October 2020. I think I missed it somehow amidst all the biogen aducanumab news anticipation around that time.
The article is written by Dr. Plotkin, the chief physics officer at ProMIS, published in Neurobiology of Disease, a journal with an impact factor of 5.5. in my experience, publishing anything in a science journal with impact factor above 4 means you go through a gauntlet of hell in terms of peer reviewer scrutiny.
Not only is he brilliant, but he communicates his analysiss in a clear and well-organized manner.
Bottom line: ProMIS Neurosciences makes no claims as to the size and maturity of the field of competitors. It tackles the competition head on with a high quality scientific approach that has tremendous potential to make it best in class. This is a useful reference for those trying to understand the scientific and business landscape.
https://www.sciencedirect.com/science/article/pii/S0969996120302850